The Prognostic Importance of Leucocytosis, Thrombocytosis and Serum Vascular Endothelial Growth Factor (VEGF) Level in Inoperable Non-Small Cell Lung Cancer (NSCLC): A Match-Pair Analysis

DEMİRKAZIK A., Asik M., Yalcin B., Dogan M., Buyukcelik A., Sencan O., ...Daha Fazla

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.20, sa.1, ss.14-19, 2010 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 1
  • Basım Tarihi: 2010
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.14-19
  • Anahtar Kelimeler: Leucocytosis, Thrombocytosis, non-Small cell lung cancer, Prognostic factor, Serum VEGF, PLATELET COUNTS, CARCINOMA, ASSOCIATION, EXPRESSION, SURVIVAL, BFGF
  • Ankara Üniversitesi Adresli: Evet

Özet

The aim of the study was to evaluate the relationship among leucocytosis, thrombocytosis and serum vascular endothelial growth factor (VEGF) levels and their prognostic value in patients with NSCLC. Fifty-five patients with histopathological and/or cytopathological diagnosed NSCLC were enrolled into the study. The patients were grouped as patients with leucocytosis (>10.000/mm(3)) and/or thrombocytosis (>400.000/mm(3)) (group 1), and others with none of them as a control group (group 2). Serum VEGF levels were measured by ELISA. Group 1 had three subgroups: patients with leucocytosis (group la), patients with thrombocytosis (group 1b) and patients with both of them (group 1c). Survival of the patients were analysed by Kaplan-Meier method. There was no survival difference between group 1 and 2, although there was a trend in favour of control group. The patients with higher levels of serum VEGF had a shorter survival than others who had lower levels, when the mean VEGF level of control group (206 pg/ml) was defined as cut-off value in group 1. The patients with leucocytosis and thrombocytosis had significantly higher VEGF levels when compared with control group (p = 0.022). No survival difference was observed for groups 1a, 1b and 1c when compared with control group. In conclusion, serum VEGF levels were significantly higher in patients who had leucocytosis and/or thrombocytosis although leucocytosis and/or thrombocytosis could not have been shown as a prognostic factor in patients with NSCLC. The association between serum VEGF and leucocytosis/thrombocytosis could not have been concluded as a cause or result.